New theobromine derivatives inhibiting VEGFR-2: design, synthesis, antiproliferative, docking and molecular dynamics simulations

Future Med Chem. 2023 Jul;15(14):1233-1250. doi: 10.4155/fmc-2023-0089. Epub 2023 Jul 19.

Abstract

Background: VEGFR-2 is one of the most effective targets in cancer treatment. Aim: The design and semi-synthesis of new theobromine derivatives as potential VEGFR-2 inhibitors. Methods: In vitro and in silico evaluation of the synthesized compounds. Results: Compound 5b demonstrated excellent antiproliferative and VEGFR-2 inhibitory effects with significant apoptotic activity. It modulated the immune response by increasing IL-2 and reducing TNF-α levels. Docking and molecular dynamics simulations revealed the compound's binding affinity with VEGFR-2. Lastly, computational absorption, distribution, metabolism, excretion and toxicity studies indicated the high potential of compound 5b for drug development. Conclusion: Compound 5b could be a promising anticancer agent targeting VEGFR-2.

Keywords: MD simulations; VEGFR-2; anticancer; apoptosis; immunomodulatory; molecular docking; semisynthesis; theobromine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Cell Proliferation
  • Drug Design
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation*
  • Molecular Structure
  • Protein Kinase Inhibitors / pharmacology
  • Structure-Activity Relationship
  • Theobromine / pharmacology
  • Vascular Endothelial Growth Factor Receptor-2

Substances

  • Theobromine
  • Vascular Endothelial Growth Factor Receptor-2
  • Protein Kinase Inhibitors
  • Antineoplastic Agents